Research ArticleCLINICAL INVESTIGATIONS
Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
Heather A. Jacene, Ross Filice, Wayne Kasecamp and Richard L. Wahl
Journal of Nuclear Medicine November 2007, 48 (11) 1767-1776; DOI: https://doi.org/10.2967/jnumed.107.043489
Heather A. Jacene
Ross Filice
Wayne Kasecamp
![Loading Loading](https://jnm.snmjournals.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 48, Issue 11
November 2007
Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
Heather A. Jacene, Ross Filice, Wayne Kasecamp, Richard L. Wahl
Journal of Nuclear Medicine Nov 2007, 48 (11) 1767-1776; DOI: 10.2967/jnumed.107.043489
Jump to section
Related Articles
Cited By...
- Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
- Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine
- Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
- Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate
- Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
- Tumor-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab Radioimmunotherapy
- Radiobiologic Optimization of Combination Radiopharmaceutical Therapy Applied to Myeloablative Treatment of Non-Hodgkin Lymphoma
- Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies
- Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients
- Predicting Hematologic Toxicity in Patients Undergoing Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan or 131I-Tositumomab
- Radioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of U.S. Medical Oncologists and Hematologists
- Radioimmunotherapy of Heavily Pre-treated, Non-Hodgkin's Lymphoma Patients: Efficacy and Safety in a Routine Setting
- Cancer Nanotargeted Radiopharmaceuticals for Tumor Imaging and Therapy
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
- 18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy
- 90Y-Ibritumomab Therapy in Refractory Non-Hodgkin's Lymphoma: Observations from 111In-Ibritumomab Pretreatment Imaging